REGENXBIO announces exclusive worldwide license with Ultragenyx for treatment of CDD
REGENXBIO announced Ultragenyx has exercised an option for an exclusive worldwide license to REGENXBIO's NAV Vectors, including NAV AAV9, for the treatment of CDKL5 Deficiency Disorder. REGENXBIO will receive an upfront payment, ongoing fees, milestone payments and royalties on net sales. October 22, 2018